medigraphic.com
Colegio de Medicina Interna de México.

2016, Number 5

<< Back Next >>

Med Int Mex 2016; 32 (5)

Tetravalent vaccine administration and its probable association to the modification of serovariety

Gómez-Piña JJ, Estrada-Hernández LO

Language: Spanish
References: 15
Page: 497-506
PDF size: 493.28 Kb.


ABSTRACT

Background: Influenza is an infectious disease which affects the respiratory tract and is characterized by the occurrence of annual (seasonal) epidemics, especially during winter seasons. Vaccination is a critical and highly effective intervention during pandemics, although is useful as a preventive method previous winter seasons too.
Objetive: To show the behavior of the different kinds of influenza, from 2009 to 2015, along each year in Regional Hospital Lic. Adolfo López Mateos, ISSSTE, focusing on influenza type B.
Material and Method: A retrospective study was done in which all the cases treated on Regional Hospital Lic. Adolfo López Mateos along seven years were collected, the population age was from less than one year to more than 65 years old.
Results: There was a predominance of women respect to men in relation 2:1. Strains AH1N1 were the dominant serovariety during the first five years of the study, although serovariety AH3N2, in the same period, maintained a constant behavior. These data resulted important because more tan 90% of the cases of influenza were caused by AH1N1 strain; in the cases of our institution 67 cases of influenza B were highlighted in the period 2014-2015, followed by influenza AH1N1 and in the third place, AH3N2.
Conclusions: Because of the fact that in the previous year the influenza B cases showed a rise on the incidence, we suggest the use of tetravalent vaccine against influenza in order to reduce influenza B cases in general population.


REFERENCES

  1. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978;298:587-592.

  2. Carr S. Seasonal and pandemic influenza: an overview with pediatric focus. Adv Pediatr 2012;59:75-93. doi: 10.1016/j. yapd.2012.04.016.

  3. Kuri-Morales P. Pandemia de influenza: la respuesta de México. Salud Pública de México 2006;48:361-444.

  4. Secretaría de Salud. Guía de manejo clínico de influenza A(H1N1) temporada otoño-invierno 2009. Diario Oficial de la Federación, 23 de octubre de 2009.

  5. Mosnier A, Caini S, Daviaud I, Nauleau E, et al. Clinical characteristics are similar across type A and B influenza virus infections. PLoS One. 2015;10:0136186. doi: 10.1371/ journal.pone.0136186.

  6. García-García L. Centro de Investigacion Sobre Enfermedades Infecciosas (CISEI). Devivavoz, gaceta informativa del INSP, edicion especial de influenza, reporte INSP, 2009. (acceso: 14 de agosto de 2015) Disponible en: http:// www.insp.mx/images/stories/INSP/Docs/ gacetas/2009/ DVV04especial.pdf

  7. Cooper K. Influenza A (H1N1). Devivavoz, gaceta informativa del INSP, edicion especial de influenza, reporte INSP, 2009. (acceso: 14 de agosto de 2015) Disponible en: http:// www.insp.mx/images/stories/INSP/Docs/ gacetas/2009/ DVV04especial.pdf

  8. Secretaria de Salud. Dirección General de Epidemiologia. Influenza, lineamientos para la vigilancia epidemiológica y laboratorio, 2014. (acceso: 30 de julio de 2015). Disponible en: http://www.epidemiologia.salud.gob.mx/doctos/ lineamientos/influenza/documento_tecnico_influenza.pdf

  9. Lopez Pio, et al. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule. Clin Vaccine Immunol 2013;20:753–758.

  10. Hernández M. Influenza: ¿por qué la necesidad de una vacuna tetravalente contra la influenza? Alergia, Asma e Inmunología Pediátricas 2014;23:39-46.

  11. Secretaría de Salud. Dirección General de Epidemiologia. Influenza. Documento técnico, febrero del2014:16-18.

  12. Programa de acción específico. Atención de urgencias epidemiológicas y desastres 2013-2018, Programa Sectorial de Salud (consultado el 19 de agosto de 2015). Disponible en: http://www.cenaprece.salud.gob.mx/ descargas/pdf/PAE_AtencionUrgenciasEpidemiologicas- Desastres2013_2018.pdf

  13. Herbinger KH, et al. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59® Adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults. Human Vaccin Immunother 2014;10:92-99.

  14. Ministerio de Sanidad, Servicios Sociales e Igualdad, Agencia Española de Medicamentos y Productos Sanitarios. Informe de Utilidad Terapeutica, Vacuna Antimeningocócica Tetravalente Conjugada, Menveo. Madrid, 2013.

  15. Aplasca-De Los Reyes MR, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother 2012;8:881-887.




2020     |     www.medigraphic.com